Monday, March 17, 2014
Rep. Henry Waxman's decision to
step down at year end, along with Rep. John Dingell's retirement and Sen. Max
Baucus' appointment as ambassador to China, leaves a deep hole in the
Democratic Party's institutional memory on issues related to healthcare in
general and FDA in particular.
But more than any other
legislator, Waxman has sculpted the U.S. healthcare landscape over the last 40
years, championing legislation that created the generic drug industry, Orphan
Drug incentives, and access to AIDS drugs.